Table 2. Toxicity of any degree related to the use of cabozantinib.
| Toxicity | Laboratory abnormalities |
|---|---|
| Diarrhea, 63% | Increase of alanine transaminase, 86% |
| Stomatitis, 51% | Increase of aspartate transaminase, 86% |
| Hand-foot syndrome, 50% | Increase of alkaline phosphatase, 53% |
| Weight loss, 48% | Reduction of calcium, 52% |
| Reduced appetite, 46% | Reduction of phosphorus, 28% |
| Nausea, 43% | Increase of bilirubins, 25% |
| Fatigue, 41% | Reduction of magnesium, 19% |
| Dysgeusia, 34% | Reduction of potassium, 18% |
| Changes in hair color, 34% | Reduction of sodium, 10% |
| Hypertension, 33% | Neutropenia, 35% |
| Constipation, 27% | Thrombocytopenia, 35% |
| Abdominal pain, 27% | Increase of TSH, 57% |
| Vomiting, 24% | |
| Dysphonia, 20% | |
| Headache, 18% | |
| Dysphagia, 13% | |
| Dyspepsia, 11% |
Adapted from Cabanillas and cols. (17).